Later work in the Vk∗MYC model has been suggestive of a pathological role for IL-17: IL-17A deficient donor grafts and inhibition of IL-17A with mAb improved MM control after BM transplant and, conversely, donor derived IL-17A promoted MM cell survival [44]. This evidence concerns the gene IL17A and Miyoshi myopathy.